The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
Zenas BioPharma Secures License Agreement with InnoCare Pharma for Autoimmune Product Candidates Including Orelabrutinib for Multiple Sclerosis
Oct 08, 2025•8 months ago
Contract Type
agreement
WalthamBiotechnologyHealth CareTherapeutics
Description
Zenas BioPharma and InnoCare Pharma have entered into a license agreement allowing Zenas to develop and commercialize orelabrutinib and two other drug candidates. The agreement includes rights to a novel IL-17AA/AF inhibitor and a TYK2 inhibitor, both aimed at treating autoimmune diseases. Zenas also announced a $120 million private placement to support its initiatives.
Company Information
Company
Zenas BioPharma
Location
1000 WINTER ST, SUITE 1200
Waltham, Massachusetts, United States
About
Zenas BioPharma is a global biopharmaceutical company committed to becoming a leader in the development and commercialization of inflammation and immunology (I&I) directed therapies for patients in need around the world. With clinical development capabilities and operations globally, Zenas is advancing a portfolio of potentially differentiated autoimmune therapeutics in areas of high unmet medical need. Our experienced leadership team and network of business partners drive operational excellence to deliver potentially transformative therapies to improve the lives of those facing autoimmune and rare diseases.
WalthamBiotechnologyHealth CareTherapeutics